Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.65    -0.10 (-5.71%)
Bid:
1.50
Ask:
1.80
Spread: 0.30 (20.00%)
Market Cap: £270.77k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Management Services Agreement

12 Sep 2019 11:45

RNS Number : 1465M
Iconic Labs PLC
12 September 2019
Β 

12 September 2019

Iconic Labs Plc ("Iconic Labs" or the "Company")

Management services agreement with Medium Channel Media Limited

Β 

Iconic Labs Plc (LSE:ICON), a multi-divisional new media and technology business is pleased to announce that it has taken a 24% shareholding in Medium Channel Media Limited ("MCM") a media focussed investment company, in return for the provision of management and consultancy services ("Management Services Agreement" or "MSA") and the provision of a loan for Β£150,000 to be used solely for working capital purposes ("the Loan"). Contemporaneously, MCM has entered into a conditional agreement to acquire Tab Media Ltd ("the Acquisition"), publishers of The Tab (www.thetab.com), the UK's leading youth and student culture focussed publisher.

Β 

The Tab is currently divided into two revenue centres: programmatic revenue; and branded content, which develops specific targeted campaigns. Under the terms of the Management Services Agreement, the senior management team of Iconic Labs will utilise their specialist experience to assist The Tab both to increase programmatic revenue by selling advertising space on The Tab's media platforms more efficiently, and increase revenue from creative services by improving The Tab's commercial presence and developing relationships with target brands.Β 

Β 

The Management Services Agreement provides for fees to be payable by MCM to the Company on a monthly basis and provide a minimum retainer revenue of no less than Β£25,000 a month. The Company believes that its team's experience in building UNILAD will be critical in ensuring the success of this strategy, which will enable The Tab to continue growing its market reach and position while at the same time improving its financial performance. The Company has also agreed with MCM that Iconic Labs will receive a substantial percentage of all profits if certain revenue and profit targets are met. The Tab achieved revenues of Β£1.28 million in the FY 2018, and the Company is confident that, with the addition of the Iconic Labs team, a significant increase in revenue and profitability is possible in the short term. The Iconic Labs board believe that the potential total revenue and cash payments to Iconic Labs will exceed Β£150,000.

Β 

MCM has been established by Starnavesse, a company controlled by Richard Thompson, one of the non-executive directors of Iconic Labs. MCM was created by Richard Thompson for the purpose of investing in media and technology companies. Richard has extensive experience in investing in public and private companies and was the founder investor in Fonix Mobile, which grew to achieve revenues of c.Β£55 million in 2018.Β 

Β 

He has declared his interest to the Company and has not participated in the Board's decisions to make this investment, provide the services of certain senior management under the MSA or provide of the Loan. The MSA shall continue until such time as either party serves notice on the other to terminate the arrangement. The Loan is repayable on demand by Iconic Labs and attracts interest at the rate of 5% per annum.

Β 

The Company will provide a further update on its investment in MCM once the acquisition of The Tab by MCM has completed.

Β 

Chief Executive Officer, John Quinlan, said: "We are constantly looking to build our platform and revenue streams to become a leading participant in the new media space. We continue to make progress at Iconic Labs and through our commercial contract and investment of 24% in Medium Channel Media we are expanding our networks and business lines. Importantly we also get to work closely with The Tab through the Management Services Agreement to build on its position as the number one market leader in the UK student market and through our investment have exposure to any future equity upside.

Β 

"Given our experience in creating UNILAD, which started as a student publisher before we developed it into the world's largest social publisher with revenues of c.Β£ 10m, we feel confident in our ability in adding value and increasing revenues at The Tab through our involvement once MCM has completed the Acquisition. We have always thought they had the most credible brand in the sector and we are looking forward to working on it through our agreement with MCM.

Β 

"We are delighted to have played such a critical role in MCM's decision to agree to acquire The Tab. The structure of MCM and the Company's investment of 24% allows us to participate in opportunities that we feel we can add significant value and build critical mass for the wider operations of the business."

Β 

Business Development Officer, Liam Harrington, said, "The Tab is the number one market leader in the student market in the country with an exciting targeted product that we believe we can assist in fulfilling its true commercial potential. With an expansive local network for distribution and quality writers and the largest presence within universities for distributing content, we believe the foundation is in place whereby we can utilise our past experience of rapidly growing social media platforms."

Β 

Β 

**ENDS**

Β 

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Β 

John Quinlan

Iconic Labs Plc

c/o SBP Tel: +44 (0) 20 7236 1177

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Erik Woolgar

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Melissa Hancock

St Brides Partners Limited

Tel: +44 (0) 20 7236 1177

Juliet Earl

St Brides Partners Limited

Tel: +44 (0) 20 7236 1177

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
AGRBGGDCXSBBGCD
Date   Source Headline
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.